• Skip to primary navigation
  • Skip to main content
Butchertown Clinical Trials

Butchertown Clinical Trials

Paid Clinical Trials in Louisville, KY

  • Blog
  • Patients
    • Currently Enrolling Clinical Trials
    • Process
    • FAQs
  • Partners
    • Physicians
    • Sponsors and CROs
    • Become a Physician Partner
    • Facility, Equipment, and Capabilities
  • About
    • Contact
    • Research Team
    • Dry Eye Research and Clinical Trials
    • Diversity, Equity, and Inclusion
    • Leave a Review
  • Show Search
Hide Search

Butchertown Clinical Trials and The Eye Care Institute Announce Our 13th FDA Approval Dextenza®, physician-inserted eye allergy treatment lasting up to 30 days

Mark Prussian · October 19, 2021 ·

October 18, 2021

For Immediate Release

Ocular Therapeutix, a Bedford MA company, has announced the FDA has approved Dextenza® for treating ocular itching associated with allergic conjunctivitis.

John C. Meyer, MD, of The Eye Care Institute and Butchertown Clinical Trials, was a principal investigator for the clinical trials leading to the FDA approval of this new treatment option for persons suffering from itchy eyes due to seasonal allergies. Dr. Meyer stated, “dissolvable implants are inserted into the puncta in an eye doctor’s office. The implants contain a preservative-free topical steroid medication which is time-released over 30 days.” Dr. Meyer continued, “the implants are painless and effective for treating allergic eye conditions with the biggest advantage being that patients should not need eye drops to relieve symptoms of allergic conjunctivitis. It’s a hands-free way to be more comfortable during allergy season.” 

Michael Goldstein, MD, President and Chief Medical Officer of Ocular Therapeutix, stated, “DEXTENZA can now provide an office-based, physician-administered, preservative-free method of steroid delivery that benefits patients with ocular itching associated with allergic conjunctivitis.”

This is the 13th FDA approved drug or device for Louisville, KY based Butchertown Clinical Trials. Mark Prussian, CEO, stated we are pleased to help allergy sufferers with our clinical trial work in this field. Many people who live in the area suffer from season allergies due to the Ohio River Valley. This trial, representing our 13th FDA approval, is just one more way we help improve human health. Depending on production and availability, these implants will soon be available in your eye doctor’s office for eye allergy suffers.

#          #          #

For More Information Contact Mark Prussian at Butchertown Clinical Trials

Butchertown Clinical Trials and The Eye Care Institute Announce Our 14th FDA Approval Tyrvaya™, the first and only nasal spray approved for signs and symptoms of Dry Eye Disease – Second Announcement in Two Days

Press Releases

best places

Butchertown Clinical Trials
205 N. Spring Street
Louisville, KY 40206

502-219-7700
Mon-Fri, 8am – 5pm

Contact Us

bct logo

Butchertown Clinical Trials is an Ophthalmic, Vaccine, Adult Medicine and Metabolic Disease Clinical Trials Research Site in Louisville, KY

eci logo

Our parent company, The Eye Care Institute, are Leaders in LASIK ® and multiple other ways to improve your vision

bbb

Copyright © 2025 · Butchertown Clinical Trials, All Rights Reserved

Website designed and supported by Louisville Web Nerds